期刊文献+

曲美他嗪对高血压合并无症状性心肌缺血患者左室重构的影响 被引量:2

Effects of Trimetazidine on Left Ventricular Remodeling in Patients of Silent Myocardial Ischemia with Hypertension
暂未订购
导出
摘要 目的观察曲美他嗪对高血压合并无症性心肌缺血(SMI)患者左心室重量、功能特征的影响。方法选择80例SMI患者应用多谱勒超声检测心脏左室结构及功能,根据有无高血压分为对照组、高血压无症状性心肌缺血(HSMI)组,对比两组左室结构、功能异同,并给予曲美他嗪治疗,观察其对左室重构及功能的影响。结果与对照组比较,HSMI组的左室后壁厚度、室间隔厚度、左室重量显著增大,舒张早期与舒张晚期峰值流速的比值(E/A)显著减小,差异有显著性(P<0.01)。治疗后HMSI组左室重量、E/A与治疗前比较差异亦有显著性(P<0.01)。结论高血压合并SMI患者多有左室结构和功能的损害,曲美他嗪可减缓、逆转左室肥厚,从而改善心脏功能。 Objective To observe effects of Trimetazidine of left ventricular remodeling in the patient of silent myocardial ischemia(SMI) with hypertension.Methods Left ventricular remodeling was detected with Doppler ultrasonic examination.Eighty cases of SMI were divided into control group(without hypertension)(n=40) and hypertension SMI(HSMI) group(n=40) and left ventricular remodeling were compared between groups.Effects of Trimetazidine on left ventricular remodeling in the HSMI group were investigated.Results Compared with the control group,thickness of the left ventricular posterior wall,thickness of the interventricular septum and left ventricular weight significantly increased,and E/A value significantly decreased(P0.01) in the HSMI group,There were significant differences in left ventricular weight and E/A in the HSMI group(P0.01)before and after treatment.Conclusion Most HSMI patients have changes of left ventricular structures and functions,and Trimetazidine can alleviate and reverse left ventricular remodeling so as to improve function of the heart.
出处 《中国医药指南》 2012年第12期56-58,共3页 Guide of China Medicine
关键词 曲美他嗪 高血压 无症状性心肌缺血 左心室重构 Trimetazidine Hypertension Silent myocardial ischemia Left Ventricular remodeling
  • 相关文献

参考文献2

二级参考文献15

  • 1Taegtmeyer H,King L M,Jones B E.Energy substrate metabolism,myocardial ischemia,and targets for pharmacotherapy[J].Am J Cardiol,1998,82(7):54K-60K.
  • 2De Leirs J,Boucher F.Rationale for trimetazidine administration in myocardial ischaemia-reperfusion yndrome[J].Eur Heart J,1993,14(S G):S34-S40.
  • 3Tabbi Anneni I,Helies Toussaint C,Morin D,et al.Prevention of heart failure in rats by trimetazidine treatment:a consequence of accelerated phospholipid turnover[J].J Pharmacol Exp Ther,2003,304(3):1003-1009.
  • 4Fox K,Ardissino D,Buszman P,et al.Guidelines on the management of stable angina pectoris[J].Eur Heart J,2006,27(11):1341-1381.
  • 5Szwed H,Sadowski Z,Pacocki R,et al.The antischemic effects and tolerability of trimetazidine in coronary diabetic patients:a substudy from TRIMPOL-1[J].Cardiovase Drug Ther,1999,13(3):217-222.
  • 6Rona G,Chappel C I,Balazs T,et al.An infact-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat[J].AMA Arch Pathol,1959,67(4):443-455.
  • 7Ocaranra M P,Diaz Araya G,Chiong M,et al.Isoprotereno1 and angiotensin I-converting enzyme in lung,left ventricle,and plasma during myocardial hypertrophy and fibrosis[J].J Cardiovase Pharmacol,2002,41(2):246-254.
  • 8Golomb E,Abassi Z A,Cude G,et al.Angiotensin Ⅱ maintains,but does not mediate,isoproterenol-induced cardiac hypertrophy in rats[J].Am J Physiol,1994,267(4):1496-1506.
  • 9Mark.DB,Nelson CL.Contining evolution of therapy for coronary artery disease[J].Circulation,1994,89:2015-2025.
  • 10Lopaschuk GD,Stanley WC.Glucose metabolism in the ischemic heart[J].Circulation,1997,95:313-315.

共引文献4

同被引文献12

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部